Liminatus Pharma, Inc. (LIMN)
NASDAQ: LIMN · Real-Time Price · USD
0.204
+0.001 (0.69%)
At close: Apr 28, 2026, 4:00 PM EDT
0.204
+0.000 (0.05%)
After-hours: Apr 28, 2026, 7:49 PM EDT

Liminatus Pharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
2.970.641.060.860.2
Research & Development
-2.693.761.853.8
Operating Expenses
2.973.334.822.714
Operating Income
-2.97-3.33-4.82-2.71-4
Interest Expense
-0.22-0.34-0.18-0.22-1.61
Interest & Investment Income
0.080.120.01--
Other Non Operating Income (Expenses)
-1.88----
EBT Excluding Unusual Items
-4.99-3.55-4.98-2.93-5.61
Other Unusual Items
-5.22----
Pretax Income
-10.21-3.55-4.98-2.93-5.61
Net Income
-10.21-3.55-4.98-2.93-5.61
Net Income to Common
-10.21-3.55-4.98-2.93-5.61
Shares Outstanding (Basic)
241810236-
Shares Outstanding (Diluted)
241810236-
Shares Change (YoY)
35.73%-82.93%188.25%--
EPS (Basic)
-0.43-0.20-0.05-0.08-
EPS (Diluted)
-0.43-0.20-0.05-0.08-
Free Cash Flow
-9.98-1.45-3.35-0.87-0.17
Free Cash Flow Per Share
-0.42-0.08-0.03-0.02-
EBITDA
-2.97---2.71-4
D&A For EBITDA
0--00
EBIT
-2.97-3.33-4.82-2.71-4
Source: S&P Capital IQ. Standard template. Financial Sources.